{"id":6947,"date":"2025-09-26T09:28:06","date_gmt":"2025-09-26T13:28:06","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&p=6947"},"modified":"2025-09-26T09:33:12","modified_gmt":"2025-09-26T13:33:12","slug":"in-vivo-car-t-therapy-for-glioblastoma-by-novel-non-viral-gene-editing-system","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/in-vivo-car-t-therapy-for-glioblastoma-by-novel-non-viral-gene-editing-system\/","title":{"rendered":"In-vivo CAR-T therapy for glioblastoma by novel non-viral gene editing system"},"content":{"rendered":"\n
\n
\n

Principal Investigator<\/strong><\/p>\n\n\n\n

Ovidiu Jumanca<\/strong>
IRCM<\/p>\n<\/div>\n\n\n\n

\n

Co-investigator<\/strong><\/p>\n\n\n\n

Christophe Brun-Baronnat
<\/b><\/span>CERASP<\/p>\n\n\n\n

Maxime Rousseaux
<\/b><\/span>University of Ottawa<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Project of <\/span>$2,394,179 over 3 years<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n
    \n
  • Supported by CQDM through:<\/strong><\/strong>
    Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n
  • And by co-funding partners:<\/strong><\/strong><\/strong>
    – Jenthera Therapeutics
    – Brain Canada Foundation<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Challenge:<\/h3>\n\n\n\n

    CAR-T therapies have delivered promising results for certain hematological cancers but remain largely ineffective for solid tumours with failure nodes. The team proposes to adapt a novel gene editing system to develop an in-vivo CAR-T gene editing treatment for glioblastoma (GBM), an aggressive type of brain cancer with a 5-year survival rate of less than 10%, through the targeted delivery of a gene editing protein and CAR encoded DNA donor to T-cells administered intravenously.<\/p>\n\n\n\n

    Solution:<\/h3>\n\n\n\n

    The research team has developed a novel gene editing platform featuring the targeted and direct delivery of the CRISPR ribonucleoprotein, a clear differentiation from current methodologies that require external agents, such as viruses or liposomes to achieve delivery of the editing complex to cells. These agents create important precision and safety issues and limit possible therapeutic applications. This approach was previously successfully applied to the direct targeting of solid tumours as well as in a CAR-T program against a hematological target where the complete eradication of the malignancies was observed at minimal starting doses through intravenous administration.<\/p>\n\n\n\n

    Expected Achievements \/Impacts<\/strong>:<\/h3>\n\n\n\n

    A systemically administered immunotherapy for GBM, ready for preclinical evaluation would change the paradigm in treatment and offer a groundbreaking, safe, non-invasive therapy to patients facing a dire prognosis with few options, harnessing the patient\u2019s own immune arsenal and offering extended immune protection against recurrence. For Jenthera therapeutics inc., this would represent a clear commercial deliverable of an in-vivo CAR construct and therapeutic approach and a proof of concept for the technology with significant commercial potential translatable to other targets within and outside of oncology. For the Quebec ecosystem, effects range from decreased pressure on health care resources to the recognition of Quebec\u2019s leading innovative force on the world stage<\/p>\n","protected":false},"featured_media":3823,"template":"","project-category":[97],"class_list":["post-6947","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-biological-and-therapeutic"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/6947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3823"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=6947"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=6947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}